Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
HS&M Magazine
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Healthcare News Roundup:
Licensing
Show More Roundups
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
HSMN NewsFeed - 7 Apr 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE(TM) Molecule
Biopharmaceuticals
Licensing
Older
Licensing
stories
Return to NewsFeed
